Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Larimar Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
Research and development
39.9
40.8
47.9
20.8
31.4
38.4
24.3
27.7
73.3
154
General and administrative
18.3
12.2
13.2
2.42
11.4
12.1
12.3
14.1
17.6
18.3
Operating expenses
58.2
53
61.1
23.2
42.8
50.5
36.5
41.8
90.9
172
Operating income
-58.2
-53
-61.1
-23.2
-42.8
-50.5
-36.5
-41.8
-90.9
-172
Interest expense
0.53
0.17
1.9
1.77
Interest income
1
1.89
1.99
Other non-operating income
0.35
0.97
-0.25
0.08
0.32
-0.17
1.17
4.81
10.3
6.82
Pre-tax income
-57.9
-52
-61.4
-23.2
-42.5
-50.6
-35.4
-36.9
-80.6
-166
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-57.9
-52
-61.4
-23.1
-42.5
-50.6
-35.4
-36.9
-80.6
-166
EBITDA
-58
-52.8
-60.9
-23.1
-42.6
-50.1
-36.2
-41.4
-90.6
-172
EPS, basic
-6.60
-5.92
-5.92
-3.80
-3.57
-2.95
-1.37
-0.84
-1.32
EPS, diluted
-6.60
-5.92
-5.92
-3.80
-3.57
-2.95
-1.37
-0.84
-1.32
Shares, basic (weighted)
8.76
8.81
10.3
6.09
11.9
17.2
25.8
43.9
61.3
Shares, diluted (weighted)
8.76
8.81
10.3
6.09
11.9
17.2
25.8
43.9
61.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
32.4
40.8
49.3
1.01
68.1
70.1
26.8
26.7
33.2
85.4
Short-term investments
96.8
61.3
68.7
43.1
24.5
91.6
60
150
51.4
Other current assets
1.36
1.93
1.73
3.74
5.31
2.11
2.31
3.39
11.9
5.17
Total current assets
131
105
121
4.75
98
72.2
121
90.2
195
142
Property, plant and equipment
0.66
0.53
0.38
0.27
1.04
1.05
0.83
0.68
0.88
0.62
Lease right-of-use assets
0.09
3.94
3.41
2.86
3.08
2.84
2.07
Other non-current assets
0.06
0.06
0.06
0.09
0.42
0.67
0.64
0.66
0.6
0.52
Total assets
132
106
122
5.2
105
78.7
126
95.9
200
146
Accounts payable
2.57
3.02
3.59
3.54
2.63
1.66
1.69
1.28
2.42
5.22
Accrued liabilities
3.73
4.27
4.26
2.26
5.84
6.59
8.41
7.39
20.9
58.5
Total current liabilities
9.89
7.29
13.3
5.9
8.99
8.85
10.7
9.51
24.4
64.8
Long-term debt
20
15.2
8.46
Lease liabilities
6.46
6
5.41
4.8
4.71
4.06
2.96
Total liabilities
9.89
27.3
28.5
5.9
15
14.3
15.5
14.2
28.4
67.8
Total debt
3.18
20
20
14.5
Paid-in capital
359
368
444
22.4
155
181
262
270
441
513
Retained earnings
-238
-290
-351
-23.1
-65.6
-116
-152
-189
-269
-435
Other comprehensive income
-0.08
-0.06
-0.03
0.04
0
-0.03
0.08
0.15
0.05
Shareholders' equity
122
78.2
2.91
-0.69
89.7
64.4
111
81.7
172
78.1
Total equity
122
78.2
2.91
-0.69
89.7
64.4
111
81.7
172
78.1
Total liabilities and equity
132
106
122
5.2
105
78.7
126
95.9
200
146
Shares outstanding
8.78
8.83
12
6.09
15.4
17.7
43.3
43.9
63.8
83.1
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-57.9
-52
-61.4
-23.1
-42.5
-50.6
-35.4
-36.9
-80.6
-166
Depreciation and amortization
0.21
0.19
0.26
0.08
0.16
0.33
0.32
0.31
0.32
0.35
Stock-based compensation
10.1
8.3
9.63
0.13
2.16
5.47
6.62
7.62
8.8
7
Change in payables
-4.63
0.45
0.43
2.63
-3.29
-0.97
0.03
-0.4
1.14
2.79
Cash from operations
-52
-43.8
-51.5
-22.7
-42.2
-42.1
-27.6
-33.5
-70.8
-113
Capital expenditures
-0.66
-0.06
-0.11
-0.08
-0.06
-0.33
-0.1
-0.16
-0.52
-0.09
Purchases of investments
-137
-115
-117
-82.9
-24.5
-8.25
-134
-101
-228
-83.6
Sales and maturities of investments
143
184
Cash from investing
51.4
35.6
-6.87
-0.08
17.1
24.2
-91
33.4
-85.4
100
Stock issued
64.9
75.6
19.9
75.3
162
65.1
Cash from financing
-2.72
16.6
66.9
19.4
93.6
19.9
75.3
0.03
162
65.1
Net change in cash
-3.24
8.43
8.55
-3.39
68.5
1.95
-43.3
-0.08
5.74
52.2
Free cash flow
-52.6
-43.8
-51.6
-22.8
-42.3
-42.4
-27.7
-33.6
-71.3
-113
Interest paid
0.39
0.14
1.14
1.22
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.08 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-135.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-104.4%
Net income / average total assets.
Return on invested capital (ROIC)
-407.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-54.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-11.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-2.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-27.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
4.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
6.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.70x
Current assets / current liabilities.
Quick ratio
4.57x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.57x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/B
2.51x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.51x
Market cap / tangible book value, when positive.
Earnings yield
-54.0%
Net income / market cap (the inverse of P/E).
Was Larimar Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $165.7M.
How much free cash flow did Larimar Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $113.2M minus capital expenditures of $91.0K left free cash flow of -$113.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.